Effects of estrogens on macrophage foam cells: A potential target for the protective effects of estrogens on atherosclerosis

Current Opinion in Lipidology

Volumn 8, Issue 5, 1997, Pages 281-286

  St Clair, Richard W ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CHOLESTEROL ESTER; ESTROGEN; LIPOPROTEIN;

ARTERY WALL; ATHEROSCLEROSIS; BIOACCUMULATION; CELL FUNCTION; ENDOTHELIUM CELL; ESTROGEN ACTIVITY; FOAM CELL; HOMEOSTASIS; MACROPHAGE; OXIDATION; PRIORITY JOURNAL; PROTECTION; SHORT SURVEY; SMOOTH MUSCLE FIBER;

ANIMALIA;

EID: 0030732957     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-199710000-00007     Document Type: Short Survey

References (82)

1. Lerner DJ, Kannel WB: Patterns of coronary heart disease morbidity and mortality in the sexes. A 26-year follow-up of the Framingham population. Am Heart J 1986, 111:383-390.
2. Godsland IF, Wynn V, Crook D, Miller NE: Sex, plasma lipoproteins, and atherosclerosis - Prevailing assumptions and outstanding questions. Am Heart J 1987, 114:1467-1503.
3. Sullivan JM, Fowlkes LP: The clinical aspects of estrogen and the cardiovascular system. Obstet Gynecol 1996, 87(suppl):36-43.
4. Stampfer MJ, Colditz GA: Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991, 20:47-63.
5. Barrett-Connor E, Bush TL: Estrogen and coronary heart disease in women. JA Md A 1991, 265:1861-1867.
6. Wahl PW, Waiden CE, Knapp RH, Wallace R, Rifkind B: Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol. N Engl J Med 1983, 308:862-867.
7. Pick R, Stamler J, Rodbard S, Katz LN: Estrogen-induced regression of coronary atherosclerosis in cholesterol-fed chicks. Circulation 1952, 6:276-280.
8. Henriksson P, Stamberger M, Eriksson M, Rudling M, Diczfalusy U, Berglund L, Angelin B: Oestrogen-induced changes in lipoprotein metabolism: role in prevention of atherosclerosis in the cholesterolfed rabbit. Eur J Clin Invest 1989, 19:395-403.
9. Hough JL, Zilversmit DB: Effect of 17 beta estradiol on aortic cholesterol content and metabolism in cholesterol-fed rabbits. Arteriosclerosis 1986, 6:57-63.
10. Haarbo J, Lethespensen P, Stender S, Christiansen C: Estrogen monotherapy and combined estrogen-progestogen replacement therapy attenuate aortic accumulation of cholesterol in ovariectomized cholesterol-fed rabbits. J Clin Invest 1991, 87:1274-1279.
11. Sulistiyani, Adelman SJ, Chandrasekaran A, Jayo J, St Clair RW: Effect of 17 α-dihydroequilin sulfate, a conjugated equine estrogen, and ethinyl estradiol on atherosclerosis in cholesterol-fed rabbits. Arterioscler Thromb Vasc Biol 1995, 15:837-846.
12. Adams MR, Kaplan JR, Manuck SB, Koritnik DR, Parks JS, Wolfe MS, Clarkson TB: Inhibition of coronary artery atherosclerosis by 17-β estradiol in ovariectomized monkeys. Arteriosclerosis 1990, 10:1051-1057.
13. Wagner JD, Clarkson TB, St Clair RW, Schwenke DC, Shively CA, Adams MR: Estrogen and progesterone replacement therapy reduces LDL accumulation in the coronary arteries of surgically postmenopausal cynomolgus monkeys. J Clin Invest 1991, 88:1995-2002.
14. Wagner JD, St Clair RW, Schwenke DS, Shively CA, Adams MR, Clarkson TB: Regional differences in arterial low density lipoprotein metabolism in surgically postmenopausal cynomolgus monkeys. Effects of estrogen and progesterone replacement therapy. Arterioscler Thromb 1992, 12:717-726.
15. Gilligan DM, Quyyumi AA, Cannon HO, Johnson GB, Schenke WH: Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation 1994, 89:2545-2551.
16. Reis SE, Gloth ST, Blumenthal RS, Resar JR, Zacur HK, Gerstenblith G, Brinker JA: Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women. Circulation 1994, 89:52-60.
17. Williams JK, Adams MR, Herrington DM, Clarkson TB: Short-term administration of estrogen and vascular responses of atherosclerotic coronary arteries. J Am Coll Cardiol 1992, 20:452-457.
18. Guetta V, Cannon RO: Cardiovascular effects of estrogen and lipid-lowering therapies in postmenopausal women. Circulation 1996, 93:1928-37.
19. Souadjian JV, Kottke BA, Titus JL: Estrogen effect on spontaneous atherosclerosis. Arch Pathol 1968, 85:463-467.
20. Hanash KA, Kottke BA, Greene LF, Titus JL: Effects of conjugated estrogens on spontaneous atherosclerosis in pigeons. Arch Pathol 1972, 93:184-189.
21. Kushwaha RS, Hazzard WR: Exogenous estrogens attenuate dietary hypercholesterolemia and atherosclerosis in the rabbit. Metabolism 1981, 30:359-366.
22. Haarbo J, Svendesen OL, Christiansen C: Progestogens do not affect aortic accumulation of cholesterol in ovariectomized cholesterol-fed rabbits. Circ Res 1992, 70:1198-1202.
23. Hanke H, Hanke S, Bruck B, Brehme U, Gugel N, Finking G, Much AO: Inhibition of the protective effect of estrogen by progesterone in experimental atherosclerosis. Atherosclerosis 1996, 121:129-138.
24. Clarkson TB, Adams MR, Williams JK, Wagner JD: Clinical implications of animal models of gender difference in heart disease. In Cardiovascular Health and Disease in Women. Edited by Douglas PS. Philadelphia: WB Saunders Co.; 1993:283-302.
25. Adams MR, Williams JK, Kaplan JR: Effects of androgens on coronary artery atherosclerosis and atherosclerosis-related impairment of vascular responslveness. Arterioscler Thromb Vasc Biol 1995, 15:562-570.
26. Larsen BA, Nordestgaard BG, Stender S, Kjeldsen K: Effect of testosterone on atherogenesis in cholesterol-fed rabbits with similar plasma cholesterol levels. Atherosclerosis 1993, 99:79-86.
27. Clarkson TB, Hughes CL, Klein KP: The nonhuman primate model of the relationship between gonadal steroids and coronary heart disease. Prog Cardiovasc Dis 1995, 38:189-198.
28. Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B, Speizer FE, Hennekens CH: Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996, 335:453-461. The relationship between cardiovascular disease and post-menopausal hormone therapy was evaluated after a 16 year follow-up in 59 337 women from the Nurses' Health Study who were 30 55 years of age at baseline. Women who took estrogen with progestin compared with women who did not take hormone therapy, had a relative risk ratio of 0.39, which was equivalent to estrogen therapy alone. Thus, addition of progestin does not attenuate the cardioprotective effects of post-menopausal estrogen therapy.
29. Akishita M, Ouchi Y, Miyoshi H, Orimo A, Kozaki K, Eto M, Ishikawa M, Kim S, Toba K, Orimo H: Estrogen inhibits endothelin-1 production and c-fos gene expression in rat aorta. Atherosclerosis 1996, 125:27-38.
30. Caulin-Glaser T, Watson CA, Pardi R, Bender JR: Effects of 17 beta-estradiol on cytokine-induced endothelial cell adhesion molecule expression. J Clin Invest 1996, 98:36-42.
31. Arnal JF, Clamens S, Pechet C, Negresalvayre A, Allera C, Girolami JP, Salvayre R, Bayard F: Ethinylestradiol does not enhance the expression of nitric oxide synthase in bovine endothelial cells but increases the release of bioactive nitric oxide by inhibiting superoxide anion production. Proc Natl Acad Sci U S A 1996, 93:4108-4113. Nitric oxide secretion is stimulated in endothelial cells by ethinylestradiol
32. Mikkola T, Ranta V, Orpano A, Ylikorkala O, Viinikka L: Effect of physiological concentrations of estradiol on PGI2 and NO in endothelial cells. Maturitas 1996, 25:141-147.
33. Rhee CY, Spaet TH, Stemmerman MB, Lajam F, Shiang HH: Estrogen suppression of surgically induced vascular intimal hyperplasia in rabbits. J Lab Clin Med 1977, 90:77-84.
34. Jacobsson J, Cheng L, Lyke K, Kuwahara M, Kagan E, Ramwell P, Foegh ML: Effect of estradiol on accelerated atherosclerosis in rabbit heterotopic aortic allografts. J Heart Lung Transplant 1992, 11:1188-1193.
35. Chen SJ, Li HB, Durand J, Oparil S, Chen YF: Estrogen reduces myointimal proliferation after balloon injury of rat carotid artery. Circulation 1996, 93:577-584.
36. Kolodgie FD, Jacob A, Wilson PS, Cartson GC, Farb A, Verma A, Virmani R: Estradiol attenuates directed migration of vascular smooth muscle cells in vitro. Am J Pathol 1996, 148:969-976.
37. Han SZ, Karaki H, Ouchi Y, Akishita M, Orimo H: 17 beta-Estradiol inhibits Ca2+ influx and Ca2+ release induced by thromboxane A (2) in porcine coronary artery. Circulation 1995, 91:2619-2626.
38. Chao TC, Phuangsab A, Vanalten PJ, Walter RJ: Steroid sex hormones and macrophage function: regulation of chemiluminescence and phagocytosis. Am J Reprod Immunol 1996, 35:106-113.
39. Tomita T, Sawamura F, Uetsuka R, Chiba T, Miura S, Ikeda M, Tomita I: Inhibition of cholesteryl ester accumulation by 17 beta-estradiol in macrophages through activation of neutral cholesterol esterase. Biochim Biophys Acta 1996, 1300:210-218. The effect of 17β-estradiol was studied in the J774 mouse macrophage cell line that had been loaded with cholesteryl esters by incubation with rabbit β-VLDL. Neutral cholesteryl ester hydrolase activity was enhanced by estrogen resulting in reduced accumulation of cholesteryl esters in macrophages. This appeared to be estrogen receptor mediated because 17 α-estradiol was without effect.
40. Frazier-Jessen MR, Kovacs EJ: Estrogen modulation of JE/monocyte chemoattractant protein-1 mRNA expression in murine macrophages. J Immunol 1995, 154:1838-1845.
41. Gulshan S, McCruden AB, Stimson WH: Oestrogen receptors in macrophages. Scand J Immunol 1990, 31:691-697.
42. Vickers AEM, Lucier G: Estrogen receptor levels and occupancy in hepatic sinusoidal endothelial and Kupffer cells are enhanced by initiation with diethylnitrosamine and promotion with 17 alpha-ethinylestradiol in rats. Carcinogenesis 1996, 17:1235-1242.
43. Inoue S, Hoshino S, Miyoshi H, Akishita M, Hosoi T, Orimo H, Ouchi Y: Identification of a novel isoform of estrogen receptor, a potential inhibitor of estrogen action, in vascular smooth muscle cells. Biochem Biophys Res Commun 1996, 219:766-772.
44. Campisi D, Cutolo M, Carruba G, Locasto M, Comito L, Granata OM, Valentino B, King RJB, Castagnetta L: Evidence for soluble and nuclear site I binding of estrogens in human aorta. Atherosclerosis 1993, 103:267-277.
45. Losordo DW, Kearney M, Kim EA, Jekanowski J, Isner JM: Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women. Circulation 1994, 89:1501-1510.
46. Farhat MY, Abi-Younes S, Ramwell PW: Non-genomic effects of estrogen and the vessel wall. Biochem Pharmacol 1996, 51:571-576.
47. Haarbo J, Nielsen LB, Stender S, Christiansen C: Aortic permeability to LDL during estrogen therapy - a study in normocholesterolemic rabbits. Arterioscler Thromb 1994, 14:243-247.
48. Wagner JD, Schwenke DC, Zhang L, Applebaum-Bowden D, Bagdade JD, Adams MR: Effects of short-term hormone replacement therapies on low density lipoprotein metabolism in cynomolgus monkeys. Arterioscler Thromb Vasc Biol 1997 17:1128-1134. Cynomolgus monkeys were given an atherogenic diet plus conjugated equine estrogen for 12 weeks at which time radiolabeled LDL was injected, and accumulation and degradation in the aorta, iliac and coronary arteries were measured. Even though conjugated equine estrogen areas reduced coronary artery atherosclerosis in a parallel group of cynomolgus monkeys by 72% (Adams MR et al. Arterioscler Thromb Vasc Biol 1997:217-221) it had no effect on LDL accumulation or degradation. In this study, after 12 weeks of cholesterol feeding there was little intimal thickening, whereas in our previous study [13], after 16 weeks of cholesterol feeding in which estrogen reduced LDL accumulation and degradation, both intimal thickening and macrophage foam cells were present. These results are consistent with the conclusion that macrophage foam cells are a target for estrogens in mediating lipoprotein accumulation and degradation in the arterial wall.
49. Rosenfeld ME, Khoo JC, Miller E, Parthasarathy S, Palinski W, Witztum JL: Macrophage-derived foam cells freshly isolated from rabbit atherosclerotic lesions degrade modified lipoproteins, promote oxidation of low-density lipoproteins, and contain oxidation-specific lipid-protein adducts. J Clin Invest 1991, 87:90-99.
50. Holm P, Andersen HO, Nordestgaard BG, Hansen BF, Kjeldsen K, Stender S: Effect of oestrogen replacement therapy on development of experimental arteriosclerosis: a study in transplanted and balloon-injured rabbit aortas. Atherosclerosis 1995, 115:191-200.
51. Wu H, Moulton KS, Glass CK: Macrophage scavenger receptors and atherosclerosis. Trends Cardiovasc Med 1992, 2:220-225.
52. Naito M, Suzuki H, Mori T, Matsumoto A, Kodama T, Takahashi K: Coexpression of Type I and Type II human macrophage scavenger receptors in macrophages of various organs and foam cells in atherosclerotic lesions. Am J Pathol 1992, 141:591-599.
53. Stanton LW, White RT, Bryant CM, Protter AA, Endemann G: A macrophage Fc receptor IgG is also a receptor for oxidized low density lipoprotein. J Biol Chem 1992, 267:22446-22451.
54. Koo C, Wernette-Hammond ME, Garcia Z, Malloy MJ, Uauy R, East C, Bilheimer DW, Mahley RW, Innerarity TL: Uptake of cholesterol-rich remnant lipoproteins by human monocyte-derived macrophages is mediated by low density lipoprotein receptors. J Clin Invest 1988, 81:1332-1340.
55. Ellsworth JL, Kraemer FB, Cooper AD: Transport of B-very low density lipoproteins and chylomicron remnants by macrophages is mediated by the low density lipoprotein receptor pathway. J Biol Chem 1987, 262:2316-2325.
56. Ottnad E, Parthasarathy S, Sambrano GR, Ramprasad MP, Quehenberger O, Kondratenki N, Green S, Steinberg DA: A macrophage receptor for oxidized low density lipoprotein distinct from the receptor for acetyl low density lipoprotein: partial purification and role in recognition of oxidatively damaged cells. Proc Natl Acad Sci U S A 1995, 92:1391-1395.
57. Seo T, St Clair RW: Heparan sulfate proteoglycans mediate internalization and degradation of β-VLDL and promote cholesterol accumulation by pigeon macrophages. J Lipid Res 1997 38:765-779.
58. Heinecke JW, Suits AG, Aviram M, Chait A: Phagocytosis of lipase-aggregated low density lipoprotein promotes macrophage foam cell formation. Sequential morphological and biochemical events. Arterioscler Thromb 1991, 11:1643-1651.
59. Sulistiyani, St Clair RW: Effect of 17β-estradiol on metabolism of acetylated low density lipoprotein by THP-1 macrophages in culture. Arterioscler Thromb Vasc Biol 1997 (in press).
60. Subbiah MTR: Effect of estrogens on the activities of cholesteryl ester synthetase and cholesteryl ester hydrolase in pigeon aorta. Steroids 1977, 30:259-275.
61. Haarbo J, Christiansen: The impact of female sex hormones on secondary prevention of atherosclerosis in ovariectomized cholesterol-fed rabbits. Atherosclerosis 1996, 123:139-144. 17 β-estradiol reduced the accumulation of cholesterol in the aorta of rabbits with pre-existing atherosclerosis, whereas the progestin levonorgestrel had no effect.
62. Small CA, Goodacre JA, Yeaman SJ: Hormone-sensitive lipase is responsible for the neutral cholesterol ester hydrolase activity in macrophages. FEBS Lett 1989, 247:205-208.
63. Contreras JA, Lusuncion MA: Essential differences in cholesteryl ester metabolism between human monocyte-derived and J774 macrophages - evidence against the presence of hormone-sensitive lipase in human macrophages. Aterioscler Thromb 1994, 14:443-452.
64. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum J: Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989, 320:915-924.
65. Witztum JL: The oxidation hypothesis of atherosclerosis. Lancet 1994, 344:793-795.
66. Endemann G, Stanton LW, Madden KS, Bryant CM, White RT, Protter AA: CD36 is a receptor for oxidized low density lipoprotein. J Biol Chem 1993, 268:11811-11816.
67. Yla-Herttuala S, Palinski W, Butler SW, Picard S, Steinberg D, Witztum JL: Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb 1994, 14:32-40.
68. Yla-Herttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, Butler S, Witztum JL, Steinberg D: Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 1989, 84:1086-1095.
69. Palinski W, Ord VA, Plump AS, Breslow JL, Steinberg D, Witztum JL: ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis demonstration of oxidation-specific epitopes in lesions and high liters of autoantibodies to malondialdehyde-lysine in serum. Arterioscler Thromb 1994, 14:605-616.
70. Henriksen T, Mahoney EM, Steinberg D: Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells- Recognition by receptors for acetylated low density lipoproteins. Proc Natl Acad Sci U S A 1981, 78:6499-6503.
71. Heinecke JW, Rosen H, Chait A: Iron and copper promote modification of low density lipoprotein by human arterial smooth muscle cells in culture. J Clin Inv 1984, 74:1890-1894.
72. Rankin SM, Parthasarathy S, Steinberg D: Evidence for a dominant role of lipoxygenase (s) in the oxidation of LDL by mouse peritoneal macrophages. J Lipid Res 1991, 32:449-456.
73. Sparrow CP, Parthasarathy S, Steinberg D: Enzymatic modification of low density lipoprotein by purified lipoxygenase plus phospholipase A2 mimics cell-mediated oxidative modification. J Lipid Res 1988, 29:745-753.
74. Wieland E, Parthasarathy S, Steinberg D: Peroxidase-dependent metal-independent oxidation of low density lipoprotein in vitro: a model for in vivo oxidation? Proc Natl Acad Sci U S A 1993, 90:5929-5933.
75. Daugherty A, Dunn JL, Rateri DL, Heinecke JW: Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 1994, 94:437-444.
76. Maziere C, Auclair M, Ronveaux M, Salmon S, Santus R, Maziere J: Estrogens inhibit copper and cell-mediated modification of low density lipoprotein. Atherosclerosis 1991, 89:175-182.
77. Taniguchi S, Yanase T, Kobayashi K, Takayanagi R, Haji M, Umeda F, Nawata H: Catechol estrogens are more potent antioxidants than estrogens for the Cu2+-catalyzed oxidation of low or high density lipoprotein: antioxidative effects of steroids on lipoproteins. Endocrine J 1994, 41:605-611.
78. Rifici VA, Khachadurian AK: The inhibition of low-density lipoprotein oxidation by 17-beta estradiol. Metab Clin Exp 1992, 41:1110-1114.
79. Subbiah MTR, Kessel B, Agrawal M, Rajan R, Abplanalp W, Rymaszewski Z: Antioxidant potential of specific estrogens on lipid peroxidation. J Clin Endocrinol Metab 1993, 77:1095-1097.
80. Sack MN, Rader DJ, Cannon HO: Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women. Lancet 1994, 343:269-270.
81. Huber LA, Scheffler E, Poll T, Ziegler R, Dresel HA: 17 Beta-estradiol inhibits LDL oxidation and cholesteryl ester formation in cultured macrophages. Free Rad Res Comms 1990, 8:167-173.
82. Jansson G: Oestrogen-induced enhancement of myeloperoxidase activity in human PMN leukocytes; a possible cause of oxidative stress in inflamatory cells. Free Rad Res Comms 1991, 14:195-208.